RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
11.45 |
uV |
3.56 |
9.42 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108537 |
3123 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
75 days
| 5 |
114.0 |
uV |
16.1 |
36.0 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
59 |
days |
|
scotopic b-wave ERG |
108703 |
3131 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
34 days
| 8 |
20.0 |
uV |
20.0 |
56.57 |
electroretinography |
cornea |
0.0 |
subretinal injection |
14 |
days |
adenovirus |
a-wave amplitude ERG |
108375 |
3121 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
53 days
| 5 |
352.0 |
uV |
26.0 |
58.14 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
37 |
days |
|
scotopic b-wave ERG |
108728 |
3131 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
5.86 |
uV |
0.76 |
2.01 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108536 |
3123 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
27.22 |
uV |
4.74 |
12.54 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108539 |
3123 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
33.73 |
uV |
9.28 |
24.55 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108540 |
3123 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
7.44 |
uV |
1.43 |
3.78 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108542 |
3123 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
251.29 |
uV |
19.14 |
50.64 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108547 |
3123 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
15.31 |
uV |
2.98 |
7.88 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108549 |
3123 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
87 days
| 5 |
83.0 |
uV |
7.0 |
15.65 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
71 |
days |
pVAX2-rGDNF |
scotopic b-wave ERG |
108735 |
3131 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
control condition then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
75 days
| 5 |
24.7 |
uV |
13.8 |
30.86 |
electroretinography |
cornea |
0.0 |
|
59 |
days |
control for age matched plasmid injection |
scotopic b-wave ERG |
108704 |
3131 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
53 days
| 5 |
96.3 |
uV |
10.3 |
23.03 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
37 |
days |
pVAX2-rGDNF |
scotopic a-wave ERG |
108725 |
3131 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
75 days
| 5 |
29.7 |
uV |
11.3 |
25.27 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
59 |
days |
pVAX2-rGDNF |
scotopic a-wave ERG |
108729 |
3131 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) and gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
70 days
| 3 |
231.0 |
uV |
5.0 |
8.66 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
54 |
days |
pVAX2 |
scotopic b-wave ERG |
108749 |
3131 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
70 days
| 3 |
199.0 |
uV |
17.0 |
29.44 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
54 |
days |
pVAX2-rGDNF |
scotopic b-wave ERG |
108750 |
3131 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
control condition then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
62 days
| 5 |
13.0 |
uV |
17.0 |
38.01 |
electroretinography |
|
0.0 |
|
0 |
|
untreated control |
b-wave amplitude ERG |
108389 |
3121 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
62 days
| 5 |
9.7 |
uV |
9.9 |
22.14 |
electroretinography |
cornea |
0.0 |
subretinal injection |
42 |
days |
adenovirus |
a-wave amplitude ERG |
108387 |
3121 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
192.0 |
uV |
14.42 |
38.15 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108545 |
3123 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
31.22 |
uV |
8.16 |
21.59 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108551 |
3123 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
94.13 |
uV |
15.33 |
40.56 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
b-wave amplitude ERG |
108556 |
3123 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
179.49 |
uV |
20.75 |
54.9 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
b-wave amplitude ERG |
108559 |
3123 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
87 days
| 5 |
24.5 |
uV |
4.9 |
10.96 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
71 |
days |
|
scotopic a-wave ERG |
108734 |
3131 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) and gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
70 days
| 3 |
23.8 |
uV |
1.9 |
3.29 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
54 |
days |
pVAX2 |
scotopic a-wave ERG |
108746 |
3131 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
control condition then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
34 days
| 8 |
13.0 |
uV |
13.0 |
36.77 |
electroretinography |
|
0.0 |
|
0 |
|
untreated control |
electrical activity measurement of retina (CMO:0003653)/A wave |
108374 |
3121 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
control condition then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
34 days
| 8 |
45.0 |
uV |
42.0 |
118.79 |
electroretinography |
|
0.0 |
|
0 |
|
untreated control |
b-wave amplitude ERG |
108377 |
3121 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
control condition then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
48 days
| 5 |
17.0 |
uV |
5.0 |
11.18 |
electroretinography |
|
0.0 |
|
0 |
|
untreated control |
a-wave amplitude ERG |
108380 |
3121 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
62 days
| 5 |
14.0 |
uV |
17.0 |
38.01 |
electroretinography |
cornea |
0.0 |
subretinal injection |
42 |
days |
adenovirus |
b-wave amplitude ERG |
108390 |
3121 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
62 days
| 5 |
34.0 |
uV |
27.0 |
60.37 |
electroretinography |
cornea |
0.0 |
subretinal injection |
42 |
days |
adenovirus |
b-wave amplitude ERG |
108391 |
3121 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
34 days
| 8 |
34.0 |
uV |
26.0 |
73.54 |
electroretinography |
cornea |
0.0 |
subretinal injection |
14 |
days |
adenovirus |
a-wave amplitude ERG |
108376 |
3121 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
48 days
| 5 |
27.0 |
uV |
22.0 |
49.19 |
electroretinography |
cornea |
0.0 |
subretinal injection |
28 |
days |
adenovirus |
a-wave amplitude ERG |
108382 |
3121 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
53 days
| 5 |
475.0 |
uV |
41.0 |
91.68 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
37 |
days |
pVAX2-rGDNF |
scotopic b-wave ERG |
108727 |
3131 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
75 days
| 5 |
135.0 |
uV |
38.0 |
84.97 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
59 |
days |
pVAX2-rGDNF |
scotopic b-wave ERG |
108731 |
3131 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
19.05 |
uV |
3.75 |
9.92 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108550 |
3123 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
159.83 |
uV |
21.35 |
56.49 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
b-wave amplitude ERG |
108558 |
3123 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
87 days
| 5 |
17.1 |
uV |
3.2 |
7.16 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
71 |
days |
pVAX2-rGDNF |
scotopic a-wave ERG |
108733 |
3131 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
87 days
| 5 |
110.0 |
uV |
14.0 |
31.3 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
71 |
days |
|
scotopic b-wave ERG |
108736 |
3131 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
53 days
| 5 |
60.2 |
uV |
8.5 |
19.01 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
37 |
days |
|
scotopic a-wave ERG |
108726 |
3131 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (15 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
70 days
| 3 |
26.7 |
uV |
2.7 |
4.68 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
54 |
days |
pVAX2-rGDNF |
scotopic a-wave ERG |
108747 |
3131 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
70 days
| 3 |
20.9 |
uV |
3.7 |
6.41 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
54 |
days |
pVAX2-rGDNF |
scotopic a-wave ERG |
108748 |
3131 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) and gene transfer of the rat GDNF gene using the plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
70 days
| 3 |
144.0 |
uV |
29.0 |
50.23 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
54 |
days |
pVAX2-rGDNF |
scotopic b-wave ERG |
108751 |
3131 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
48 days
| 5 |
17.0 |
uV |
18.0 |
40.25 |
electroretinography |
cornea |
0.0 |
subretinal injection |
28 |
days |
adenovirus |
a-wave amplitude ERG |
108381 |
3121 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
control condition then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
62 days
| 5 |
8.9 |
uV |
9.9 |
22.14 |
electroretinography |
|
0.0 |
|
0 |
|
untreated control |
a-wave amplitude ERG |
108386 |
3121 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
48 days
| 5 |
110.0 |
uV |
40.0 |
89.44 |
electroretinography |
cornea |
0.0 |
subretinal injection |
28 |
days |
adenovirus |
b-wave amplitude ERG |
108385 |
3121 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
75 days
| 5 |
114.0 |
uV |
16.0 |
35.78 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
59 |
days |
|
scotopic b-wave ERG |
108732 |
3131 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
145.24 |
uV |
12.56 |
33.23 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108544 |
3123 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
3.13 |
uV |
1.81 |
4.79 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108548 |
3123 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
24.79 |
uV |
7.82 |
20.69 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108552 |
3123 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
32.75 |
uV |
13.42 |
35.51 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
b-wave amplitude ERG |
108555 |
3123 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
131.7 |
uV |
16.13 |
42.68 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
b-wave amplitude ERG |
108557 |
3123 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
48 days
| 5 |
51.0 |
uV |
33.0 |
73.79 |
electroretinography |
cornea |
0.0 |
subretinal injection |
28 |
days |
adenovirus |
b-wave amplitude ERG |
108384 |
3121 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
62 days
| 5 |
11.0 |
uV |
12.0 |
26.83 |
electroretinography |
cornea |
0.0 |
subretinal injection |
42 |
days |
adenovirus |
a-wave amplitude ERG |
108388 |
3121 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
53 days
| 5 |
352.0 |
uV |
26.0 |
58.14 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
37 |
days |
|
scotopic b-wave ERG |
108701 |
3131 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
control condition then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
53 days
| 5 |
186.0 |
uV |
23.8 |
53.22 |
electroretinography |
cornea |
0.0 |
|
37 |
days |
control for age matched plasmid injection |
scotopic b-wave ERG |
108702 |
3131 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
34 days
| 8 |
39.0 |
uV |
23.0 |
65.05 |
electroretinography |
cornea |
0.0 |
subretinal injection |
14 |
days |
adenovirus |
b-wave amplitude ERG |
108378 |
3121 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
gene transfer of the lin-28 homolog B gene using an adenovirus vector (5250000 PFU) then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
34 days
| 8 |
79.0 |
uV |
43.0 |
121.62 |
electroretinography |
cornea |
0.0 |
subretinal injection |
14 |
days |
adenovirus |
b-wave amplitude ERG |
108379 |
3121 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
control condition then controlled exposure to darkness (for 12 hours) |
Tao Z, et al., Oncotarget. 2016 Aug 2;7(31):49368-49383. doi: 10.18632/oncotarget.10343. |
rod electrophysiology trait |
both |
48 days
| 5 |
48.0 |
uV |
26.0 |
58.14 |
electroretinography |
|
0.0 |
|
0 |
|
untreated control |
b-wave amplitude ERG |
108383 |
3121 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
18.53 |
uV |
4.77 |
12.63 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108538 |
3123 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
36.49 |
uV |
10.37 |
27.44 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108541 |
3123 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
83.4 |
uV |
14.8 |
39.16 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108543 |
3123 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
233.29 |
uV |
18.61 |
49.24 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108546 |
3123 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
31.96 |
uV |
9.73 |
25.74 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108553 |
3123 |
RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
phosphate buffered saline (4 ul) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39 days
| 7 |
10.28 |
uV |
1.69 |
4.47 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
b-wave amplitude ERG |
108554 |
3123 |
RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
gene transfer using empty plasmid vector pVAX2 (30 ug) then controlled exposure to darkness (for 1 days) then visible light stimulus (3 cd x s/m2) |
Touchard E, et al., Gene Ther. 2012 Sep;19(9):886-98. doi: 10.1038/gt.2011.154. Epub 2011 Oct 13. |
rod electrophysiology trait |
both |
75 days
| 5 |
23.1 |
uV |
4.0 |
8.94 |
electroretinography |
cornea |
0.0 |
plasmid delivery |
59 |
days |
|
scotopic a-wave ERG |
108730 |
3131 |